Alcoholism, Fibroblast Growth Factor 23 and Cardiovascular Risk

Abstract

Background: Bone metabolism is tightly regulated by several hormones that are synthesized in bone cells and have effects not only on bone but on several distant organs. These hormones are involved in intermediate metabolism and modulate fatty acid transport, playing a role in insulin resistance, liver steatosis, atherosclerosis and cardiovascular risk.

Aims: We review the association of fibroblast growth factor-23 (FGF-23) and α-Klotho with cardiovascular risk, especially in the alcoholic patient.

Results: High levels of FGF-23 are associated with vascular risk, especially with vascular calcifications, hypertension, or left ventricular hypertrophy.

Main Findings: Hyperphosphatemia constitutes a major stimulus for FGF-23 secretion, together with inflammation and reduced iron availability, either by iron deficiency or by iron sequestration in inflammatory diseases. FGF-23 can be expressed by the damaged liver. Alcoholism is a proinflammatory condition, and in alcoholics there is an increased cardiovascular risk. Preliminary data suggest that FGF-23 is raised in alcoholics.

Conclusion: Increased FGF-23 levels have been described in association with hypertension, arterial wall calcification, left ventricular hypertrophy and increased cardiovascular mortality, both in patients with or without chronic kidney disease. Some data suggest that FGF-23 is also related to increased vascular risk in alcoholics.

Brief Summary: FGF-23 is an osteocyte derived molecule related to cardiovascular risk. Hyperphosphatemia is a major trigger mechanism for its secretion, but inflammatory conditions are also associated with increased FGF-23 production. Some data suggest that FGF-23 may be also related with the increased vascular risk observed in chronic alcoholic patients.

Background

Bone is a metabolically active organ, in which synthesis and resorption are coupled in order to adapt its structure and mechanical properties to load changes and to provide calcium, phosphorus, and alkaline salts to the rest of the body. This process is tightly regulated by several hormones, mainly synthesized by bone cells or by liver, kidneys or parathyroid glands. In contrast with the classic perception of bone only as a reservoir of calcium, phosphorus and alkaline buffers [1], in the last decades it has become increasingly evident that bone is an endocrine organ, capable of exerting diverse functions in distant structures such as liver, adipocyte, muscle, kidneys, heart or brain [2,3]. The discovery of the transformation of vascular smooth muscle cells into bone-forming cells, governed by the same hormones that are involved in bone remodeling, has aided in our understanding of all these effects [4]. Indeed, major bone-derived hormones play an outstanding role in atherosclerosis, as depicted in figure 1.

In the past years, an osteocyte derived growth factor, fibroblast growth factor-23 (FGF-23) initially described as a phosphatonin, has been subjected to intensive research, mainly because of its association with hypertension and cardiovascular risk. Very recently, some studies also point out that osteocytes increase FGF-23 synthesis in inflammatory conditions, so it can be considered a marker of inflammation. Also, it has been shown that FGF-23 can be produced by the damaged liver. The purpose of this study is to provide an overview about the association of this molecule with hypertension...
and cardiovascular risk, and to discuss its potential role in vascular complications related to alcoholism, both because of the smoldering systemic inflammation caused by alcoholism, and because of the eventual liver damage exerted by chronic ethanol consumption.

**FGF-23-A Klotho Axis**

In 2000, Yamashita et al isolated the Fibroblast growth factor (FGF)-23, that was expressed in the brain and thymus of adult mice [5]. In the same year a form of autosomal dominant hypophosphatemic rickets (ADHR) was described that was characterized by a mutation in the FGF-23 gene [6].

Later it was shown that osteoblasts and osteocytes are the main source of circulating FGF-23 in vivo. The secretion of FGF-23 by bone is stimulated by vitamin D and by extracellular phosphate, calcium and PTH [7,8].

Serum phosphate levels are finely regulated by hormonal signals. Transepithelial transport of phosphate in the intestine and in the kidney is carried out by sodium/phosphate cotransporters (NaPi-2a, NaPi-2b, NaPi-2c). Several hormonal factors such as parathyroid hormone (PTH), active metabolites of vitamin D and FGF-23 can control the activity of these cotransporters [9].

In 2004, Shimada et al demonstrated that FGF-23 is a potent regulator of vitamin D and phosphate metabolism. After administration of recombinant FGF-23 to parathyroidectomized animals there was a reduction in serum levels of phosphate and calcitriol. The reduction in serum phosphate was associated with a decrease in renal mRNA of the cotransporter NaPi-2a. They found no increase in PTH levels throughout the experiment. FGF-23 also decreased renal mRNA for 1α hydroxylase and increased mRNA for 24–hydroxylase [10]. The direct down-regulation effect of FGF-23 on the membrane expression the sodium–phosphate cotransporter NaPi-2a in the proximal tubule was also reported by Andrukhova et al [11]. The effect on 1α hydroxylase also affects monocytes, impairing immune response [12]. Despite the phosphaturic effect of FGF-23, it inhibits parathyroid hormone (PTH) secretion [13], although the underlying mechanisms are still unclear [14].

It has been recently shown that another mechanism involved in FGF-23 synthesis is iron deficiency or the so called “functional iron deficiency”, i.e., iron sequestration in inflammatory setting [15], probably via HIF induction of the FGF-23 gene transcription. Interestingly, induction of FGF-23 synthesis by acute inflammation is accompanied by a parallel increase in the cleaving ability of the osteocyte, leading to increased levels of carboxy- terminal FGF-23 (c-FGF-23), and normal or near normal serum levels of intact FGF-23 (i-FGF-23). By contrast, in chronic inflammation, both products are increased, probably because the cleavage capacity of the osteocyte becomes overwhelmed by continuous FGF-23 overproduction [16,17].

The metabolic effects of FGF-23 require binding of this molecule to a receptor complex that includes FGF receptors (FGFR) and the transmembrane protein αKlotho. There are 4 types of FGFR (FGFR1, 2, 3 and 4) but it is believed that FGF-23 acts through a receptor complex that includes FGFR-1c and αKlotho (although αKlotho can also bind to FGFR3 and 4). Signaling using the FGF–Rt receptor seems to be involved in the regulation of FGF–23 secretion in osteoblasts and osteocytes but the intracellular pathways that regulate this process are still unknown [14].

It seems clear that αKlotho functions as a co-receptor for FGF–23 and increases FGFR’s affinity for FGF-23 20-fold [14]. αKlotho is a transmembrane protein that serves as a coreceptor for FGF-23, strongly increasing the affinity of this molecule for the FGFR receptors [14,18]. The main sites for αKlotho expression are choroid plexus in the central nervous system, parathyroid glands, and proximal and distal renal tubules [14].

αKlotho exhibits an extracellular domain that is cleaved, generating the soluble form of αKlotho [19], that can be measured in blood, urine and cerebrospinal fluid. The function of αKlotho is a controversial issue. It was originally described as an anti-aging factor. In 1997, Kuro-o et al described a defect in the expression of the αklotho gene in mice. These mice developed a syndrome similar to aging in humans which included shortened lifespan, infertility, atherosclerosis, skin atrophy, osteoporosis and emphysema [20]. However, after the ablation of vitamin D signaling using mice that lacked a vitamin D receptor (VDR) this phenotype disappeared [21]. Mice with aKlotho and FGF–23 deficits produce excessive amounts of vitamin D because there is no suppressive effect of FGF-23 on the activity of renal 1α hydroxylase activity. Because of this, it is believed that the early aging phenotype seen in mice without aKlotho and FGF–23 is due to vitamin D intoxication that leads
to severe hypercalcemia and hyperphosphatemia with organ dysfunction [14].

Although α-Klotho deficiency has been associated with early aging, atherosclerosis, and vascular calcifications, other authors have described a paradoxical increase in α-Klotho levels in situations associated with oxidative stress. Nakanishi et al. studied α-Klotho levels in men and they found higher soluble α-Klotho and IL-6 levels in smokers than in subjects who had never smoked. They conclude that the increase in soluble α-Klotho levels is a compensatory response to stress and that α-Klotho acts as an anti-inflammatory molecule [22]. The recent discovery that inflammation results in an increased FGF-23 secretion adds a new interpretation to raised α-Klotho in situations of oxidative stress.

FGF-23 is heavily involved in bone metabolism [9], given its close relationship with PTH, vitamin D, calcium and phosphorus. The relationships between FGF-23/α-Klotho levels and bone mineral density (BMD) have been analysed in several studies, but findings show either a weak relationship with BMD [23,24] or no relationship at all [25]. On the contrary, several studies have reported close relationships between FGF-23 and vascular risk, as commented later.

**Effects of FGF-23/α-Klotho on the cardiovascular system**

FGF-23 levels are directly related to the progression of chronic kidney disease, left ventricular hypertrophy, vascular calcification, and increased mortality in patients with chronic renal disease [14]. Gutiérrez et al. found that high levels of FGF-23 at the start of hemodialysis were independently associated with mortality [26]. Faul et al. found that high FGF-23 levels in patients with chronic kidney disease were associated with a lower ejection fraction, high left ventricular mass index, and a higher prevalence of left ventricular hypertrophy [27]. In addition, it has been described that FGF-23 is an independent risk factor for all-cause mortality and cardiovascular mortality in patients with normal renal function who were subjected to coronary angiography [28]. Other researchers have reported higher FGF-23 levels in patients with obesity, especially visceral fat accumulation [29], suggesting an indirect relationship with cardiovascular risk in patients with intact renal function. Additionally, it was shown that FGF-23 is a marker of frailty among community-dwelling individuals [30]. Also, FGF-23 is related with arterial stiffness in diabetic patients, independently on estimated glomerular filtration rate [31]. Therefore, the relationship of FGF with cardiovascular risk extends far beyond chronic kidney failure.

FGF-23 can indirectly promote cardiovascular and renal disease by contributing to sodium and water retention. Andrukhova et al., administered recombinant FGF-23 to mice and they found an increase in the reabsorption of sodium in the distal tubule with subsequent volume expansion, hypertension and cardiac hypertrophy that was dependent on the amount of sodium administered through diet. Chlorothiazide, an inhibitor of sodium reabsorption, prevented volume expansion mediated by FGF-23 and cardiac hypertrophy [11]. However, other authors have failed to find any relation between FGF-23 and volume changes, at least in patients with diabetic nephropathy [32]. FGF-23 levels did not change either after saline fluid overload or after treatment with hydrochlorotiazide, low sodium diet and angiotensin converting enzyme inhibitors. Furthermore, Grabner et al. demonstrated that binding of FGF-23 to its receptor FGFR4 in cardiomyocytes induces myocyte hypertrophy (via phospholipase C and calcineurin). An antibody that blocks the binding of FGF-23 to FGFR4 inhibits cardiac hypertrophy induced by FGF-23 in rats with chronic kidney disease [33]. Therefore, cardiac hypertrophy is not necessarily dependent upon the existence of hypertension.

It is not yet known whether FGF-23 can directly affect vascular cells. Scialla et al. found no association between FGF-23 levels and vascular calcification in coronary arteries and in the thoracic aorta assessed using computed tomography. They also studied human and mouse vascular smooth muscle and found that FGF-23 had no effect on phosphate induced calcification, not even in the presence of soluble α-Klotho [34]. However, Jimbo et al. showed that FGF-23 increased phosphate-induced vascular calcification in aortic rings of uremic rats [35]. It has been proposed that FGF-23 and α-Klotho are not directly involved in the pathogenesis of vascular calcification; on the contrary, increased levels of both proteins would be due to a compensatory mechanism [36]. FGF-23 would rise in order to counteract increased deposition of calcium phosphate salts.

As was described earlier, an antiaging effect has been described for α-Klotho and in this sense it has been proposed that this molecule might have a cardioprotective effect. However, no association was found between soluble α-Klotho levels and vascular risk in patients with chronic kidney disease in a recent cohort study [37].

**FGF-23 and Alcoholic liver disease**

Although FGF-23 has been primarily linked to bone metabolism, recent studies show an association with liver function. Nafid et al., (2009) reported that partial hepatectomy led to increased FGF-23 levels [38], and later, Raimann et al., (2013) showed that liver tissue could express mRNA for FGF-23 [39]. In the same year Prie et al. found that high FGF-23 levels predict the risk of death in patients with end stage liver disease on a liver transplant waiting list [40]. In these patients, high FGF-23 levels were not explained by decreased renal function. They also found in an experimental model that the damaged liver of diethyl-nitrosamine–treated mice expressed FGF-23 mRNA whereas healthy livers of control mice did not [40]. Additionally, in a more recent study by Wasserman et al high FGF-23 levels were described in 2 infants with liver disease due to biliary atresia who had developed a form of hypophosphatemic rickets. They also found that the damaged liver overexpressed FGF-23 [41]. Therefore, altered FGF-23 levels may be associated with liver disease. The link between FGF-23 and the bone–liver–vascular axis has not yet been completely elucidated.

Similar observations have been performed, logically, with α-Klotho. In the mentioned study by Raimann et al [39],

these authors found that piglets’ liver may express α Klotho, and Chen et al., (2013) also report that human hepatoma cells may express α Klotho. Staining positivity for α Klotho was also associated with the presence of liver cirrhosis [42]. This is in contrast with the observations of Lim et al, who, in 2015, described expression of transmembrane α Klotho in many tissues, but not in the liver. However, they did not study diseased liver [43]. It is possible that, in a way similar to FGF-23, only diseased liver expresses alpha Klotho.

Altered iron homeostasis in liver disease, especially among alcoholics [44], might also explain increased FGF-23 in this disease. As mentioned before, sequestered iron, via HIF, may trigger an excessive production of FGF-23 by the hepatocyte. Indeed, alcoholism is a proinflammatory condition, especially if the liver is involved [45]. Ethanol increases intestinal permeability, leading to increased leakage of Gram negative (and also, to a lesser extent, Gram positive bacteria) from intestine to portal blood [46]. These bacteria activate Kupffer cells [47], leading to increased secretion of proinflammatory cytokines. In addition, the diseased liver, especially if there are portosystemic shunts, as is the case of liver cirrhosis, cannot achieve an adequate defence against the increased portal endotoxemia [48]. Systemic endotoxemia leads to a generalized immune response, and therefore, to a generalized proinflammatory situation [49]. Whether or not this suffices to activate osteocyte-mediated FGF-23 secretion, and/or the damaged liver can also directly synthesize FGF-23 is not known. In a preliminary report we have observed increased FGF-23 levels in a group of alcoholics, especially in cirrhotics [50].

Ethanol consumption may lead to hypertension. It has been known since several decades that the association of ethanol consumption and hypertension adapts to a J- or U-shaped curve, but to a linear one [51]. Different studies have also pointed out that ethanol consumption – especially in the form of distilled beverages– is associated with left ventricular hypertrophy [52], a finding that has been interpreted as a compensatory mechanism of the heart exposed to increased afterload in hypertensive patients.

The pathogenesis of the relationship between ethanol and hypertension is unclear. There are many studies relative to the effect of ethanol on nitric oxide synthase, some with contradictory results [53,54]. Increased arterial stiffness has been also reported in alcoholics, perhaps in association with increased levels of oxidized LDL, increased expression of adhesion molecules in monocytes [55] and increased atherogenesis [56]. A fascinating hypothesis is that this increased inflammatory status triggers increased secretion of FGF-23 and this in turn causes or contributes to vascular calcification, hypertension and left ventricular hypertrophy in alcoholics. All of this is still speculative, but research in this field is urgently needed.

**Conclusion**

This review illustrates the emerging role of bone as an endocrine organ. FGF-23, as an osteocyte-derived product is an example of the systemic effects of bone derived molecules that not only have a role in phosphate metabolism but are also related to vascular risk. Although only partially known, this molecule is also related to some a priori unexpected functions, such as hippocampal neurogenesis and learning [57]. Indeed, the fact that chronic inflammation triggers its secretion, together with its protein systemic effects, makes it plausible that it is perhaps involved in several manifestations of common conditions in which a smoldering inflammatory process ensues, as it may happen in the cardiovascular manifestations of alcoholism.

**Author Contributions**


**References**


